Farha Khan, MD
Endocrinology, Diabetes & Metabolism · Coon Rapids, MNNPI 1730121765
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $287,254 of the $348,529 with a category attached, or 82.4%. 28 manufacturers reported payments, led by Novo Nordisk at 40.4% of the total. Among endocrinology, diabetes & metabolism clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $649.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$141K
- Lilly USA, LLC$82K
- AstraZeneca$45K
- Dexcom, Inc.$35K
- Abbott$28K
- Insulet Corporation$16K
- plus $3K from 22 others
What the payments were for
- Consulting fees$11,4183%
- Speaking & faculty fees$287,25482%
- Travel & lodging$41,41112%
- Food & beverage$8,0452%
- Education$4020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 160 | $140,691 |
| Lilly USA, LLC | 171 | $81,887 |
| AstraZeneca(2 entities) | 53 | $44,661 |
| Dexcom, Inc. | 40 | $34,644 |
| Abbott | 35 | $27,657 |
| Insulet Corporation | 27 | $16,474 |
| Corcept Therapeutics | 1 | $1,400 |
| E.r. Squibb & Sons, L.L.C. | 1 | $297 |
| Medtronic(2 entities) | 5 | $102 |
| Ascensia Diabetes Care US Inc. | 5 | $88 |
| Bayer | 5 | $86 |
| BETA Bionics, Inc. | 5 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Radius Health, Inc. | 4 | $52 |
| Ultragenyx Pharmaceutical Inc. | 3 | $46 |
| Recordati_rare_diseases_inc. | 3 | $42 |
| Tandem Diabetes Care, Inc. | 2 | $38 |
| Companion Medical, Inc. | 2 | $24 |
| Valeritas, Inc. | 1 | $24 |
| Amgen | 2 | $24 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Cequr Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$76,750
- MOUNJARO$65,886
- FARXIGA$44,280
- RYBELSUS$34,975
- DEXCOM G7 GSS (161)$34,031
- FREESTYLE LIBRE 3$23,317
- Omnipod$16,141
- Tresiba$10,465
- DEXCOM STELO GLUCOSE BIOSENSOR$7,372
- Victoza$4,793
- FreeStyle Libre Pro$3,900
- Xultophy 100/3.6$2,601
- Korlym$1,400
- ORENCIA$297
How this compares
$348,529 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 222 | $323,935 |
| MounjaroTirzepatide | 181 | $235,440 |
| JardianceEmpagliflozin | 148 | $184,633 |
| TrulicityDulaglutide | 52 | $91,499 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $68,909 |
| Humulin R U-500Insulin Regular, Human | 14 | $27,039 |
| FarxigaDapagliflozin Propanediol | 18 | $26,435 |
| Bydureon BciseExenatide Microspheres | 12 | $21,278 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $19,826 |
| JanuviaSitagliptin Phosphate | 11 | $18,519 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $13,866 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $11,727 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $10,957 |
| Levothyroxine Sodium | 432 | $8,806 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $7,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $81,887 | $333,009261 claims |
| Novo NordiskOzempic, Novolog | $140,691 | $330,612240 claims |
| AstraZenecaFarxiga | $44,661 | $26,43518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Coon Rapids
- Kathryn O'DayCoon Rapids$1K
- Richard BergenstalSt Louis Park$595K
- Mark HolmSaint Cloud$318K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
- Sidney JonesChaska$67K
- Maria CastroRochester$63K
- Marius StanRochester$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.